Innate Pharma SA
IPHA
Company Profile
Business description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Contact
117, Avenue de Luminy
Marseille13009
FRAT: +33 430303030
E: investors@innate-pharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
179
Stocks News & Analysis
stocks
The ASX healthcare player soaring to all-time highs
The steep market reaction comes after a recent announcement by the ACCC
stocks
Ask the analyst: How long is WiseTech's growth runway?
Roy Van Keulen answers my question on how big a growth opportunity remains for the ASX's biggest technology company.
video
Why the ASX's most overlooked world champion is no dinosaur
Brambles is the undisputed king of pallet pooling. Esther Holloway joined me to talk about its moat, growth prospects and risk of disruption.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,416.60 | 57.70 | -0.68% |
| CAC 40 | 7,541.36 | 63.58 | 0.85% |
| DAX 40 | 19,120.93 | 105.52 | 0.55% |
| Dow JONES (US) | 42,352.75 | 341.16 | 0.81% |
| FTSE 100 | 8,280.63 | 1.89 | -0.02% |
| HKSE | 22,736.87 | 623.36 | 2.82% |
| NASDAQ | 18,137.85 | 219.37 | 1.22% |
| Nikkei 225 | 38,635.62 | 83.56 | 0.22% |
| NZX 50 Index | 12,619.94 | 47.28 | 0.38% |
| S&P 500 | 5,751.07 | 51.13 | 0.90% |
| S&P/ASX 200 | 8,150.00 | 55.20 | -0.67% |
| SSE Composite Index | 3,336.50 | 248.97 | 8.06% |